<DOC>
	<DOCNO>NCT01610947</DOCNO>
	<brief_summary>Patients spondyloarthritis , already treat TNF blocker ( adalimumab , etanercept infliximab ) , stable low disease activity least 6 month , randomize 2 group : either keep usual treatment stable dos progressive space injection treatment . Follow-up do every 3 month 12 month , regular monitoring disease activity , patient group `` spacing '' , modification rhythm injection accord health state predefined protocol .</brief_summary>
	<brief_title>Effect Spacing Anti-TNF Drugs Ankylosing Spondylitis With Low Disease Activity</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Adult patient spondyloarthritis accord ASAS criterion Stable low disease activity least 6 month Already treat TNF block drug ( adalimumab , etanercept infliximab ) Raised acute phase reactant participation another clinical trial Structural progression peripheral joint damage Scheduled surgery within 12 month pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Spondyloarthritis</keyword>
	<keyword>Anti-TNF</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Infliximab</keyword>
</DOC>